English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/122541
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

From bitopic inhibitors to multitarget drugs for Alzheimer’s disease future treatment

Otros títulosFrom bitopic inhibitors to multitarget drugs for the future treatment of Alzheimer’s disease
AutorPérez, Daniel I.; Martínez, Ana ; Gil, Carmen ; Campillo, Nuria E.
Palabras claveAlzheimer’s disease
Bitopic drugs
Multitarget
BACE-1
Cannabinoids
GSK3β
AChE
BuChE
Fecha de publicación2015
EditorBentham Science Publishers
CitaciónCurrent Medicinal Chemistry, Volume 22 (E-pub ahead of print) (2015)
ResumenDementia is one of the main causes of disease burden for developed regions. According to the World Health Organization (WHO), these diseases will become the world’s second leading cause of death by the middle of the century, overtaking cancer. This will have a dramatic impact in medical care, as well as important social and economic implications, unless more effective preventive procedures or treatments become available. Alzheimer’s disease (AD) is the most common cause of dementia, accounting for probably 50-75% of all dementias worldwide, followed by vascular dementia, mixed dementia, and Lewy body dementia. Currently, drugs being used to treat AD are AChE inhibitors such as donepezil, rivastigmine and galantamine, for mild to moderate stages. Alternative therapy in its severe stage is memantine, an antagonist of the NMDA-subtype glutamate receptors. However, these drugs only provides temporary benefits by improving symptoms, but do not alter disease progression, except temporarily, in some patients. During the past years different approaches have been developed to provide a more efficient treatment for AD. In addition to the discovery of emerging targets and new drugs aiming at a single target, given the complexity of the disease different targets should be engaged simultaneously. Strategies have explored bitopic inhibitors- acting on different sites of the acetylcholinesterase enzyme producing at least two different activities- to multi-target drugs-acting on different therapeutic targets. In this review, we explore the journey from bitopic inhibitor strategy to multi-target drugs for future AD treatment.
Descripción34 p.-17 fig.
Versión del editorhttp://benthamscience.com/journal/abstracts.php?journalID=cmc&articleID=133938
URIhttp://hdl.handle.net/10261/122541
DOI10.2174/0929867322666150812145825
ISSN0929-8673
E-ISSN1875-533X
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Curr.Med. Chem._Martínez, A._2015.docxPostprint1 MBMicrosoft Word XMLVisualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.